Compare PAYS & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYS | SIGA |
|---|---|---|
| Founded | 2001 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.7M | 341.0M |
| IPO Year | 2020 | 2016 |
| Metric | PAYS | SIGA |
|---|---|---|
| Price | $6.99 | $4.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.42 | N/A |
| AVG Volume (30 Days) | ★ 603.8K | 439.7K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 13.24% |
| EPS Growth | ★ 85.71 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $24,120,434.00 | N/A |
| Revenue This Year | $33.83 | N/A |
| Revenue Next Year | $14.89 | $224.81 |
| P/E Ratio | $74.33 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.08 | $4.10 |
| 52 Week High | $8.88 | $9.62 |
| Indicator | PAYS | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 56.41 | 41.87 |
| Support Level | $5.05 | $4.26 |
| Resistance Level | $8.04 | $4.84 |
| Average True Range (ATR) | 0.42 | 0.11 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 36.76 | 14.41 |
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.